Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.45 USD | +0.94% | +6.44% | -43.62% |
Financials (USD)
Sales 2024 * | 410M | Sales 2025 * | 465M | Capitalization | 1.02B |
---|---|---|---|---|---|
Net income 2024 * | 63M | Net income 2025 * | 99M | EV / Sales 2024 * | 2.48 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.19 x |
P/E ratio 2024 * |
12.8
x | P/E ratio 2025 * |
8.16
x | Employees | 267 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.36% |
Latest transcript on Ironwood Pharmaceuticals, Inc.
1 day | -1.99% | ||
1 week | +5.97% | ||
Current month | +1.43% | ||
1 month | -21.31% | ||
3 months | -31.44% | ||
6 months | -38.26% | ||
Current year | -44.14% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas McCourt
CEO | Chief Executive Officer | 66 | 08-12-31 |
Sravan Emany
DFI | Director of Finance/CFO | 46 | 21-12-05 |
Marcel Moulaison
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alexander Denner
BRD | Director/Board Member | 54 | 20-11-08 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-12-02 |
Mark Currie
BRD | Director/Board Member | 69 | 18-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.50% | 28 M€ | -2.42% | ||
0.42% | 25 M€ | -3.43% | - | |
0.35% | 1,085 M€ | +9.49% | - | |
0.20% | 43 M€ | +2.89% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 6.45 | +0.94% | 1 969 254 |
24-06-05 | 6.39 | -1.99% | 2,220,593 |
24-06-04 | 6.52 | -4.26% | 3,755,500 |
24-06-03 | 6.81 | +8.10% | 3,314,033 |
24-05-31 | 6.3 | +3.96% | 2,883,238 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.14% | 1.02B | |
+55.70% | 59.34B | |
+41.08% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- IRWD Stock